Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Mar 15;18(6):1493-5.
doi: 10.1158/1078-0432.CCR-11-3266. Epub 2012 Feb 2.

Phospho-specific flow: fixating on the target

Mark Levis  1
Affiliations
Comment

Phospho-specific flow: fixating on the target

Mark Levis. Clin Cancer Res. .

Abstract

Targeted therapies are all the rage in oncology research these days. The problem remains as to how to confirm that the target is actually being hit in vivo. This report describes the application of phospho-specific flow cytometry to establish in vivo target inhibition in real time.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Analyzing patient samples with phospho-specific flow
A small amount of a commercially-available fixative (formaldehyde-based) is added to a fresh blood sample. The sample can then be shipped to a central lab or processed immediately. After lysis of red blood cells permeabilization, the sample is incubated with antibodies to the phosphorylated targeted prior to analysis by flow cytometry.
Figure 2
Figure 2
See this image and copyright information in PMC

Comment on

References

    1. Perl AE, Kasner MT, Shank D, Luger SM, Carroll M. Single-cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy. Clin Cancer Res. 2012:18. - PMC - PubMed
    1. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005;106:4261–8. - PMC - PubMed
    1. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292–302. - PubMed
    1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7. - PubMed
    1. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108:3477–83. - PMC - PubMed

MeSH terms

Supplementary concepts